Neurophet and RapidAI Partner to Expand Access to Alzheimer's and MS Treatment Monitoring

- Agreement expands Neurophet's reach into U.S. health systems and builds on RapidAI's leadership in enterprise clinical AI and neurosciences

SEOUL, South Korea, Nov. 2, 2026 /PRNewswire/ -- Neurophet, an artificial intelligence (AI) solution company for brain disorders diagnosis and treatment, today announced a partnership with RapidAI, a global leader in enterprise clinical AI, to integrate Neurophet's advanced neurodegenerative brain imaging solutions into the Rapid Enterprise Platform.

Backed by deep clinical expertise in neurosciences, RapidAI's enterprise platform combines advanced imaging AI with workflow solutions that connect radiology and clinical teams throughout the patient journey. RapidAI's solutions are trusted by more than 2,500 hospitals across 100 countries worldwide.

The partnership will accelerate commercialization of the globally established Neurophet solution into the U.S. market by integrating into RapidAI's platform. The Neurophet comprehensive brain imaging analysis solution includes Neurophet AQUA AD Plus and Neurophet SCALE PET, designed to support the prescription of Alzheimer's disease treatments, brain health, and dementia patient management.

The portfolio also includes Neurophet AQUA MS, a quantitative imaging analysis software solution for multiple sclerosis (MS). Integrated into Neurophet AQUA, Neurophet AQUA MS analyzes brain images of patients with MS, an intractable disease of the central nervous system.

Neurophet AQUA AD Plus uses AI-powered brain magnetic resonance imaging (MRI) analysis to automatically identify and quantify the locations and number of hypointense lesions associated with cerebral microbleeds and superficial siderosis, as well as hyperintense lesions associated with brain edema.

These imaging findings are particularly important for monitoring potential treatment-related side effects in patients with Alzheimer's disease receiving anti-amyloid therapies, such as Leqembi and Kisunla. By providing quantitative insights into these brain changes, the solution seeks to support clinicians in assessing treatment safety and making more informed decisions throughout the course of Alzheimer's disease treatment.

By combining RapidAI's established U.S. hospital and healthcare customer base with Neurophet's AI-powered brain imaging technology, the companies aim to expand access to advanced neuroimaging solutions and support more informed clinical decision-making.

"We plan to complete the integration of Neurophet AQUA AD Plus into RapidAI and begin full-scale product distribution, focusing on memory disorders centers in the U.S. that prescribe Leqembi and Kisunla," said Jake Junkil Been, Co-CEO of Neurophet.

He added, "We will further expand the platform integration to include Neurophet AQUA and Neurophet SCALE PET, establishing a comprehensive solution delivery framework that covers the entire continuum of dementia care, from diagnosis to treatment monitoring."

Through the Rapid Enterprise Platform, Neurophet's advanced neuroimaging capabilities are integrated into the workflows radiologists and care teams already use. Radiologists will be able to access AI-generated insights through Rapid Navigator Pro, while clinicians can access results through the Rapid Mobile App, helping teams review findings and coordinate patient care.

The integration reflects RapidAI's deep expertise and commitment to continued innovation across the neuroscience service line. It gives health systems a consistent way to access and manage specialized clinical AI solutions through shared infrastructure and centralized AI governance. Together, these capabilities aim to support more informed treatment decisions and longitudinal monitoring for patients with neurodegenerative diseases.

About Neurophet

Neurophet (Co-CEOs Jake Junkil Been and Donghyeon Kim) specializes in developing solutions for diagnosis support, treatment guides, and treatment devices targeting brain disorders based on cutting-edge artificial intelligence (AI) technology. The company was founded in 2016 by Co-CEOs Jake Junkil Been and Donghyeon Kim, who developed the next-generation neuro-navigation system.

Major products include brain MRI analysis software "Neurophet AQUA", PET Image Quantitative Analysis Software "Neurophet SCALE PET", Brain imaging treatment planning software for electric and magnetic brain stimulation "Neurophet tES/TMS LAB", Alzheimer's Disease treatment prescription and monitoring software "Neurophet AQUA AD" for tracking treatment efficacy and side effects, and Multiple Sclerosis image analysis software "Neurophet AQUA MS".

Neurophet has set its top priority to helping patients suffering from brain disorders. Based on expertise in neuroscience, Neurophet will continue to challenge and grow to explore the human brain's health and pioneer solutions for brain diseases with AI technology.

About RapidAI

RapidAI is a global leader in enterprise clinical AI, trusted by more than 2,500 hospitals across 100+ countries and backed by 800+ clinical studies. The Rapid Enterprise™ Platform combines 50+ RapidAI-developed and third-party algorithms spanning neurology, cardiac and vascular, trauma, and oncology care. Paired with enterprise workflow solutions that connect radiology and clinical teams throughout the patient journey, it turns imaging and patient data into actionable clinical context, moving radiologists and clinicians from detection to confident action. Powered by Rapid Edge Cloud and built to integrate with existing workflows and health IT systems, it helps health systems reduce fragmentation, improve collaboration, and deliver faster, more consistent care across the enterprise. Learn more at RapidAI.com

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

Neurophet and RapidAI Partner to Expand Access to Alzheimer's and MS Treatment Monitoring

Peptide 9 Bio Sun Stick Pro and targeted neck care lead the brand's U.S. department store debut.

SEOUL, South Korea, Nov. 3, 2026 /PRNewswire/ -- MDP+, a Korean derma skincare brand, today announced its launch at Nordstrom, marking its first entry into the U.S. department store channel.

The brand will launch on Nordstrom.com and roll out in phases to seven select Nordstrom stores, with broader availability through Nordstrom Rack stores nationwide and online. The launch builds on MDP+'s presence on Amazon, TikTok Shop, and Olive Young Global.

The Nordstrom assortment highlights MDP+'s signature Peptide 9 collection and targeted neck care products.

The Peptide 9 Bio Sun Stick Pro is an SPF 50 sunscreen stick designed for easy, mess-free reapplication throughout the day, including over makeup. It has become a standout product for MDP+ in the U.S., with more than 450,000 units sold on TikTok Shop to date. The broader Peptide 9 collection features peptide-based formulas designed to support skin firmness and volume.

The Neck Care collection includes the Collagen Naite Thread Neck Cream, known for its distinctive thread-like texture, and the Naite 1000 Shot Neck Stick. The assortment also features products from MDP+'s Red Lacto Collagen collection.

An expanded eight-product assortment will be available on Nordstrom.com and through Nordstrom Rack, both in stores nationwide and online. Additional offerings include the Red Lacto Collagen Wrapping Mask, Red Lacto Collagen Clear Foam Cleanser, Red Lacto Collagen Cleansing Oil, Peptide 9 Volume & Tension Cream Pro, and Peptide 9 Volume Ampoule Pro.

MDP+ will roll out in phases to the following Nordstrom locations: Downtown Seattle in Seattle, Washington; Oakbrook Center in Oak Brook, Illinois; Mission Viejo, California; Arcadia, California; Frisco, Texas; Coral Gables, Florida; and Ala Moana Center in Honolulu, Hawaii.

"Launching at Nordstrom is an important milestone as we continue to build MDP+ in the U.S.," said an MDP+ spokesperson. "Building on our growth on Amazon and TikTok Shop, we're focused on introducing more U.S. consumers to MDP+ and our approach to Korean derma skincare through a broader mix of retail channels."

About MDP+

MDP+ is the U.S. brand of MEDIPEEL, drawing on more than 15 years of Korean derma and esthetic skincare expertise. The brand specializes in targeted skincare, including anti-aging skincare, neck care and sun care. Its formulas feature ingredients such as peptides, PDRN and collagen, with select products supported by clinical testing.

Contact: 

Sooji Kang
sooji.kang@medipeel.com 
+82-32-572-5690

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

Korean Derma Skincare Brand MDP+ Launches at Nordstrom